These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 11305808)

  • 21. Improved response to erythropoietin in peritoneal dialysis patients as compared to hemodialysis patients: role of iron deficiency.
    Raja R; Bloom E; Johnson R; Goldstein M
    Adv Perit Dial; 1994; 10():135-8. PubMed ID: 7999811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impacts of recombinant human erythropoietin treatment during predialysis periods on the progression of chronic kidney disease in a large-scale cohort study (Co-JET study).
    Akizawa T; Saito A; Gejyo F; Suzuki M; Nishizawa Y; Tomino Y; Tsubakihara Y; Akiba T; Hirakata H; Watanabe Y; Kawanishi H; Bessho M; Udagawa Y; Aoki K; Uemura Y; Ohashi Y;
    Ther Apher Dial; 2014 Apr; 18(2):140-8. PubMed ID: 24720404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of anemia in patients with chronic renal insufficiency undergoing hemodialysis with recombinant human erythropoietin: 12 months' experience].
    de Sousa FT; Prata MM; Barbas JV; dos Santos JP
    Acta Med Port; 1990; 3(6):347-52. PubMed ID: 2089856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized prospective comparison between erythropoietin and androgens in CAPD patients.
    Navarro JF; Mora C; Macía M; García J
    Kidney Int; 2002 Apr; 61(4):1537-44. PubMed ID: 11918762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of hematocrit variations on cerebral blood flow and oxygen transport in ischemic cerebrovascular disease.
    Kusunoki M; Kimura K; Nakamura M; Isaka Y; Yoneda S; Abe H
    J Cereb Blood Flow Metab; 1981; 1(4):413-7. PubMed ID: 7328151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predialysis versus postdialysis hematocrit evaluation during erythropoietin therapy.
    Movilli E; Pertica N; Camerini C; Cancarini GC; Brunori G; Scolari F; Maiorca R
    Am J Kidney Dis; 2002 Apr; 39(4):850-3. PubMed ID: 11920353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigation of the efficacy of a biogeneric recombinant human erythropoietin alfa in the management of renal anemia in patients on hemodialysis: a multi-center clinical trial.
    Beiraghdar F; Panahi Y; Einollahi B; Nemati E; Ghadiani MH; Sahebkar A; Maghsoudi N; Marzony ET
    Clin Lab; 2012; 58(7-8):737-45. PubMed ID: 22997974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trends in anemia at initiation of dialysis in the United States.
    Obrador GT; Roberts T; St Peter WL; Frazier E; Pereira BJ; Collins AJ
    Kidney Int; 2001 Nov; 60(5):1875-84. PubMed ID: 11703606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cerebral blood flow and oxygen delivery during hypoxemia and hemodilution: role of arterial oxygen content.
    Todd MM; Wu B; Maktabi M; Hindman BJ; Warner DS
    Am J Physiol; 1994 Nov; 267(5 Pt 2):H2025-31. PubMed ID: 7977834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of angiotensin-converting enzyme inhibitors on the treatment of anemia with erythropoietin.
    Hayashi K; Hasegawa K; Kobayashi S
    Kidney Int; 2001 Nov; 60(5):1910-6. PubMed ID: 11703610
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative effects of erythropoietin with oral iron in peritoneal dialysis and hemodialysis patients.
    Raja R; Bloom E; Johnson R
    Adv Perit Dial; 1993; 9():177-80. PubMed ID: 8105918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
    Nakamoto H; Mimura T; Honda N
    Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum transferrin receptor concentration is not indicative of erythropoietic activity in chronic hemodialysis patients with poor response to recombinant human erythropoietin.
    Hou CC; Wu SC; Wu SC; Yang WC; Huang TP; Ng YY
    Zhonghua Yi Xue Za Zhi (Taipei); 1998 Aug; 61(8):456-62. PubMed ID: 9745161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Reticulocyte response after immediate withdrawal of recombinant human erythropoietin in chronic hemodialysis patients].
    Caramelo C; Soto C; Neira F; López MD; Jiménez S; Albalate M; de Oña R; Llamas P; Deudero JJ
    Nefrologia; 2004; 24(4):351-6. PubMed ID: 15455495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Normalization of hematocrit with recombinant human erythropoietin in chronic hemodialysis patients does not fully improve their exercise tolerance abilities.
    Suzuki M; Tsutsui M; Yokoyama A; Hirasawa Y
    Artif Organs; 1995 Dec; 19(12):1258-61. PubMed ID: 8967885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of erythropoietin on muscle O2 transport during exercise in patients with chronic renal failure.
    Marrades RM; Roca J; Campistol JM; Diaz O; Barberá JA; Torregrosa JV; Masclans JR; Cobos A; Rodríguez-Roisin R; Wagner PD
    J Clin Invest; 1996 May; 97(9):2092-100. PubMed ID: 8621799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cellular bioenergetics after erythropoietin therapy in chronic renal failure.
    Marrades RM; Alonso J; Roca J; González de Suso JM; Campistol JM; Barberá JA; Diaz O; Torregrosa JV; Masclans JR; Rodríguez-Roisin R; Wagner PD
    J Clin Invest; 1996 May; 97(9):2101-10. PubMed ID: 8621800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
    Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
    Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cerebral blood flow velocity during isovolemic hemodilution and subsequent autologous blood retransfusion.
    Mühling J; Dehne MG; Sablotzki A; Hempelmann G
    Can J Anaesth; 1999 Jun; 46(6):550-7. PubMed ID: 10391602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of uremia and dialysis on brain electrophysiology after recombinant erythropoietin treatment.
    Di Paolo B; Di Liberato L; Fiederling B; Catucci G; Bucciarelli S; Paolantonio L; Albertazzi A
    ASAIO J; 1992; 38(3):M477-80. PubMed ID: 1457906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.